<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medvis</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская визуализация</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Visualization</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-0763</issn><issn pub-type="epub">2408-9516</issn><publisher><publisher-name>RDS-Media Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24835/10.24835/1607-0763-1087</article-id><article-id custom-type="elpub" pub-id-type="custom">medvis-1087</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОТ ПРИГЛАШЕННОГО РЕДАКТОРА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FROM THE INVITED EDITOR</subject></subj-group></article-categories><title-group><article-title>Оценка возможности применения позитронно-эмиссионной компьютерной томографии с применением 18F-фтордезоксиглюкозы у пациентов с метастазами из невыявленного первичного очага в области головы и шеи</article-title><trans-title-group xml:lang="en"><trans-title>The role of PET-CT with 18F-FDG in initial assessment of patients with carcinoma of unknown primary (CUP) in the head and neck</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7709-977X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яременко</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yaremenko</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яременко Степан Андреевич – аспирант кафедры лучевой диагностики и лучевой терапии</p><p>119192 Москва, Ломоносовский проспект, 27, к.10</p></bio><bio xml:lang="en"><p>Stepan A. Yaremenko – PhD student, Department of Radiology Diagnostics </p><p>27-10, Lomonosovsky prospekt, 119192, Moscow</p></bio><email xlink:type="simple">yaremenkosa@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8063-4462</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ручьева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rucheva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ручьева Наталья Александровна – канд. мед. наук, заведующая отделением лучевой диагностики</p><p>123182 Москва, Щукинская ул., д. 1</p></bio><bio xml:lang="en"><p>Natalia A. Rucheva – Cand. of Sci. (Med.), Head of the department radiology diagnostics </p><p>1, Shchukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">rna1969@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5649-2193</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синицын</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Sinitsin</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Синицын Валентин Евгеньевич – доктор мед. наук, профессор, заведующий отделом лучевой диагностики, заведующий кафедрой лучевой диагностики и лучевой терапии факультета фундаментальной медицины</p><p>Scopus ID 7102735724</p><p>119192 Москва, Ломоносовский проспект, 27, к.10</p></bio><bio xml:lang="en"><p>Valentin E. Sinitsin – Doct. of Sci. (Med.), Professor, Head of Radiology department, Chief of Radiology and Radiotherapy Chair, Faculty of Fundamental Medicine</p><p>27-10, Lomonosovsky prospekt, 119192, Moscow</p></bio><email xlink:type="simple">vsini@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский научно-образовательный центр ФГБОУ ВО “Московский государственный университет имени М.В. Ломоносова”</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Research and Education Center of Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ “Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Shumakov National Medical Research Center of Transplantology and Artificial Organs</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>05</day><month>03</month><year>2022</year></pub-date><volume>26</volume><issue>1</issue><fpage>21</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яременко С.А., Ручьева Н.А., Синицын В.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Яременко С.А., Ручьева Н.А., Синицын В.Е.</copyright-holder><copyright-holder xml:lang="en">Yaremenko S.A., Rucheva N.A., Sinitsin V.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medvis.rdsmedia.ru/jour/article/view/1087">https://medvis.rdsmedia.ru/jour/article/view/1087</self-uri><abstract><p>Введение. Метастазы рака из невыявленного первичного очага (НПО) в области головы и шеи включают большую гетерогенную группу опухолевых образований, первичную локализацию которых не удалось установить даже после тщательного диагностического поиска. Позитронно-эмиссионная томография в сочетании с компьютерной томографией с 18-фтордезоксиглюкозой (ПЭТ-КТ с 18F-ФДГ) имеет высокий уровень обнаружения первичных новообразований в результате одновременного получения точно совмещенных анатомических и функциональных изображений всего тела.Задачи исследования. Оценить возможность применения ПЭТ-КТ с 18F-ФДГ у пациентов с метастазами из НПО в области головы и шеи.1. Определить эффективность ПЭТ-КТ для обнаружения первичного опухолевого очага у пациентов с гистологически верифицированным диагнозом НПО в области головы и шеи.2. Оценить вклад методики ПЭТ-КТ в оценку распространенности заболевания у пациентов с диагнозом НПО в области головы и шеи.Материал и методы. За период с сентября 2018 г. по март 2019 г. в ретроспективное исследование было включено в общей сложности 134 пациента с диагнозом метастазов рака из НПО в области головы и шеи: 35 (26,1%) из них женщины и 99 (73,9%) – мужчины. Средний возраст пациентов, включенных в исследование, составил 61,9 ± 7,5 года. Всем пациентам перед ПЭТ-КТ была проведена пункционная биопсия как минимум одного метастатического очага и гистологически верифицирован злокачественный характер новообразования, а также был проведен ряд стандартных исследований в рамках онкопоиска для выявления природы первичного опухолевого очага.Результаты. Среди 134 пациентов, включенных в исследование, наблюдалось следующее распределение гистологических вариантов опухоли (по данным биопсии метастатических лимфатических узлов): 82 (61,2%) пациента с диагнозом плоскоклеточного рака, 5 (3,7%) пациентов с диагнозом меланомы, 20 (15%) пациентов с недифференцированной карциномой, 21 (15,6%) пациент с аденокарциномой и 6 (4,5%) пациентов с недифференцированным злокачественным новообразованием.В ходе исследования первичную локализацию опухоли удалось установить у 72 (54%) пациентов, у 62 (46%) оставшихся пациентов первичный источник не был обнаружен. Возраст пациентов в группах с выявленным и не выявленным первичным очагом после проведения ПЭТ-КТ достоверно не отличался.Новые, не выявленные ранее метастатические очаги были обнаружены при проведении ПЭТ-КТ у 60 пациентов, что составило 44,7% от всей выборки. Стоит отметить, что изменение в оценке распространенности опухолевого процесса после проведения ПЭТ-КТ произошло в 95 (71%) случаях, что было связано как с обнаружением первичной опухоли, так и с выявлением новых метастатических очагов.Выводы. Применение ПЭТ-КТ позволяет точнее определить стадию онкологического процесса у значительной части пациентов с НПО в области головы и шеи. В значительной части случаев метод позволяет выявить первичную опухоль, что, в свою очередь, оказывает влияние на тактику лечения и прогноз у данных пациентов. Применение ПЭТ-КТ должно обязательно включаться в план обследования пациентов с метастазами рака из НПО в области головы и шеи.</p></abstract><trans-abstract xml:lang="en"><p>Introduction. Cancer metastases from an unknown primary origin (CUP) in the head and neck area include a large heterogeneous group of tumor formations, the primary localization of which could not be established even after a thorough diagnostic search. Combined positron emission computed tomography (PET-CT) with 18F-FDG has a high level of detection of primary neoplasms as a result of simultaneous acquisition of precisely combined anatomical and functional images of the entire body.Objectives. 1. To evaluate the possibility of using PET-CT (positron emission tomography in combination with computed tomography) with 18F-FDG (18-fluorodeoxyglucose) in patients with metastases from the CUP (carcinoma unknown primary) in the head and neck.2. To determine the effectiveness of PET-CT for the detection of primary tumor focus in patients with histologically verified diagnosis of CUP in the head and neck.3. To evaluate the contribution of the PET-CT technique in assessing the prevalence of the disease in patients diagnosed with head and neck cancer.Materials and methods. 134 patients diagnosed with CUP in the head and neck from September 2018 to March 2019 were included to this retrospective study: 35(26.1%) women and 99(73.9%) men, with the mean age of 61.9 ± 7.5 years. All patients underwent a biopsy from at least one metastatic lesion, and the malignant nature of the neoplasm was histologically verified. Before PET-CT with 18F-FDG, standard oncological evaluation was carried out to detect primary tumor.Results. Among 134 patients comprised the study, initial histological diagnoses were: squamous cell cancer (n = 82, 61.2%), melanoma (n = 5, 3.7%), undifferentiated carcinoma (n = 20, 15%), adenocarcinoma (n = 21, 15.6%) and undifferentiated malignant neoplasm (n = 6, 4.5%).With PET-CT with 18F-FDG, primary tumor location was revealed in 72 (54%) of the patients. New metastatic lesions were found in 60 (44.7%) of the patients.Change in the TNM stage was observed in 95(71%) of all cases after PET-CT with 18F-FDG. It was associated both with the detection of the primary tumor and the identification of new metastatic foci.Conclusions. Use of PET-CT with 18F-FDG allows to carry out oncological evaluation more precisely than the standard procedures in the majority of patients with CUP in the head and neck region. In a significant quota of cases, this method is in a position also to help to identify the primary tumor lesion, which, in turn, influences on strategy of treatment and also on the prognosis of disease. PET-CT with 18F-FDG should be included to the protocol of radiological examination in patients with CUP in the head and neck anatomic area.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ПЭТ-КТ</kwd><kwd>НПО</kwd><kwd>рак</kwd><kwd>18Ф-ФДГ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>PET-CT</kwd><kwd>CUP</kwd><kwd>cancer</kwd><kwd>18F-FDG</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Abbruzzese J.L., Abbruzzese M.C., Lenzi R., Hess K.R., Raber M.N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol. 1995; 13 (8): 2094–2103. http://doi.org/10.1200/JCO.1995.13.8.2094</mixed-citation><mixed-citation xml:lang="en">Abbruzzese J.L., Abbruzzese M.C., Lenzi R., Hess K.R., Raber M.N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol. 1995; 13 (8): 2094–2103. http://doi.org/10.1200/JCO.1995.13.8.2094</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012; 379 (9824): 1428–1435. http://doi.org/10.1016/S0140-6736(11)61178-1</mixed-citation><mixed-citation xml:lang="en">Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012; 379 (9824): 1428–1435. http://doi.org/10.1016/S0140-6736(11)61178-1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wagland R., Bracher M., Drosdowsky A. et al. Differences in expe riences of care between patients diagnosed with metastatic cancer of known and unknown primaries: Mixed-method findings from the 2013 cancer patient experience survey in England. BMJ Open. 2017; 7 (9): 1–10. http://doi.org/10.1136/bmjopen-2017-017881</mixed-citation><mixed-citation xml:lang="en">Wagland R., Bracher M., Drosdowsky A. et al. Differences in expe riences of care between patients diagnosed with metastatic cancer of known and unknown primaries: Mixed-method findings from the 2013 cancer patient experience survey in England. BMJ Open. 2017; 7 (9): 1–10. http://doi.org/10.1136/bmjopen-2017-017881</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Qaseem A., Usman N., Jayaraj J.S. et al. Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site. Cureus. 2019; 11 (9): e5552. http://doi.org/10.7759/cureus.5552</mixed-citation><mixed-citation xml:lang="en">Qaseem A., Usman N., Jayaraj J.S. et al. Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site. Cureus. 2019; 11 (9): e5552. http://doi.org/10.7759/cureus.5552</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bochtler T., Löffler H., Krämer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin. Diagn. Pathol. 2018; 35 (3): 199–206. http://doi.org/10.1053/j.semdp.2017.11.013</mixed-citation><mixed-citation xml:lang="en">Bochtler T., Löffler H., Krämer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin. Diagn. Pathol. 2018; 35 (3): 199–206. http://doi.org/10.1053/j.semdp.2017.11.013</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cetin Avci N., Hatipoglu F., Alacacıoglu A. et al. FDG PET/ CT and conventional imaging methods in cancer of unknown primary: an approach to overscanning. Nucl. Med. Mol. Imaging. 2018; 52 (6): 438–444. http://doi.org/10.1007/s13139-018-0544-7</mixed-citation><mixed-citation xml:lang="en">Cetin Avci N., Hatipoglu F., Alacacıoglu A. et al. FDG PET/ CT and conventional imaging methods in cancer of unknown primary: an approach to overscanning. Nucl. Med. Mol. Imaging. 2018; 52 (6): 438–444. http://doi.org/10.1007/s13139-018-0544-7</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cengiz A., Göksel S., Yürekli Y.. Diagnostic Value of 18F-FDG PET/CT in Patients with Carcinoma of Unknown Primary. Mol. Imaging Radionucl. Ther. 2018; 27 (3): 126–132. http://doi.org/10.4274/mirt.64426</mixed-citation><mixed-citation xml:lang="en">Cengiz A., Göksel S., Yürekli Y.. Diagnostic Value of 18F-FDG PET/CT in Patients with Carcinoma of Unknown Primary. Mol. Imaging Radionucl. Ther. 2018; 27 (3): 126–132. http://doi.org/10.4274/mirt.64426</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Send T., Kreppel B., Gaertner F.C., Bundschuh R.A., Strunk H., Bootz F., Essler M. PET-CT bei Karzinomen im Kopf-Hals-Bereich. HNO. 2017; 65 (6): 504–513. http://doi.org/10.1007/s00106-017-0355-7</mixed-citation><mixed-citation xml:lang="en">Send T., Kreppel B., Gaertner F.C., Bundschuh R.A., Strunk H., Bootz F., Essler M. PET-CT bei Karzinomen im Kopf-Hals-Bereich. HNO. 2017; 65 (6): 504–513. http://doi.org/10.1007/s00106-017-0355-7</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Burglin S.A., Hess S., Høilund-Carlsen P.F., Gerke O. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary. Med (United States). 2017; 96 (16): 1–8. http://doi.org/10.1097/MD.0000000000006713</mixed-citation><mixed-citation xml:lang="en">Burglin S.A., Hess S., Høilund-Carlsen P.F., Gerke O. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary. Med (United States). 2017; 96 (16): 1–8. http://doi.org/10.1097/MD.0000000000006713</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Aro K., Bäck L., Mäkitie A., Tapiovaara L. An evaluation of the diagnostic methods in head and neck cancer of unknown primary site. Acta Otolaryngol [Internet]. 2018; 138 (10): 930–936. http://doi.org/10.1080/00016489.2018.1484567</mixed-citation><mixed-citation xml:lang="en">Aro K., Bäck L., Mäkitie A., Tapiovaara L. An evaluation of the diagnostic methods in head and neck cancer of unknown primary site. Acta Otolaryngol [Internet]. 2018; 138 (10): 930–936. http://doi.org/10.1080/00016489.2018.1484567</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cianchetti M., Mancuso A.A., Amdur R.J. et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope. 2009; 119 (12): 2348–2354. http://doi.org/10.1002/lary.20638</mixed-citation><mixed-citation xml:lang="en">Cianchetti M., Mancuso A.A., Amdur R.J. et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope. 2009; 119 (12): 2348–2354. http://doi.org/10.1002/lary.20638</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Maghami E., Ismaila N., Alvarez A. et al. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. J. Clin. Oncol. 2020; 38 (22): 2570–2596. http://doi.org/10.1200/JCO.20.00275</mixed-citation><mixed-citation xml:lang="en">Maghami E., Ismaila N., Alvarez A. et al. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. J. Clin. Oncol. 2020; 38 (22): 2570–2596. http://doi.org/10.1200/JCO.20.00275</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Reinert C.P., Sekler J., la Fougère C. et al. Impact of PET/ CT on clinical management in patients with cancer of unknown primary – a PET/CT registry study. Eur. Radiol. 2020; 30 (3): 1325–1333. http://doi.org/10.1007/s00330-019-06518-9</mixed-citation><mixed-citation xml:lang="en">Reinert C.P., Sekler J., la Fougère C. et al. Impact of PET/ CT on clinical management in patients with cancer of unknown primary – a PET/CT registry study. Eur. Radiol. 2020; 30 (3): 1325–1333. http://doi.org/10.1007/s00330-019-06518-9</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Roh J.L., Kim J.S., Lee J.H. et al. Utility of combined (18) F-fluorodeoxyglucose-positron emission tomography and computed tomo graphy in patients with cervical metastases from unknown primary tumors. Oral. Oncol. 2009; 45 (3): 218–124. http://doi.org/10.1016/j.oraloncology.2008.05.010</mixed-citation><mixed-citation xml:lang="en">Roh J.L., Kim J.S., Lee J.H. et al. Utility of combined (18) F-fluorodeoxyglucose-positron emission tomography and computed tomo graphy in patients with cervical metastases from unknown primary tumors. Oral. Oncol. 2009; 45 (3): 218–124. http://doi.org/10.1016/j.oraloncology.2008.05.010</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gutzeit A., Antoch G., Kühl H. et al. Unknown primary tumors: Detection with dual-modality PET/CT – Initial experience. Radiology. 2005; 234 (1): 227–234. http://doi.org/10.1148/radiol.2341031554</mixed-citation><mixed-citation xml:lang="en">Gutzeit A., Antoch G., Kühl H. et al. Unknown primary tumors: Detection with dual-modality PET/CT – Initial experience. Radiology. 2005; 234 (1): 227–234. http://doi.org/10.1148/radiol.2341031554</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nanni C., Rubello D., Castellucci P. et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: Preliminary results in 21 patients. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (5): 589–592. http://doi.org/10.1007/s00259-004-1734-3</mixed-citation><mixed-citation xml:lang="en">Nanni C., Rubello D., Castellucci P. et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: Preliminary results in 21 patients. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (5): 589–592. http://doi.org/10.1007/s00259-004-1734-3</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Goel R., Moore W., Sumer B. et al. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. Am. J. Roentgenol. 2017; 209 (2): 289–303. http://doi.org/10.2214/AJR.17.18301</mixed-citation><mixed-citation xml:lang="en">Goel R., Moore W., Sumer B. et al. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. Am. J. Roentgenol. 2017; 209 (2): 289–303. http://doi.org/10.2214/AJR.17.18301</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Koç Z.P., Kara P.Ö., Dağtekin A. Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography. CNS Oncol. 2018; 7 (2): CNS12. http://doi.org/10.2217/cns-2017-0018</mixed-citation><mixed-citation xml:lang="en">Koç Z.P., Kara P.Ö., Dağtekin A. Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography. CNS Oncol. 2018; 7 (2): CNS12. http://doi.org/10.2217/cns-2017-0018</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Aassar O.S., Fischbein N.J., Caputo G.R. et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999; 210 (1): 177–181. http://doi.org/10.1148/radiology.210.1.r99ja48177</mixed-citation><mixed-citation xml:lang="en">Aassar O.S., Fischbein N.J., Caputo G.R. et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999; 210 (1): 177–181. http://doi.org/10.1148/radiology.210.1.r99ja48177</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
